PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
Details
Publication Year 2024-09,Volume 131,Issue #5,Page 820-831
Journal Title
British Journal of Cancer
Publication Type
Research article
Abstract
BACKGROUND: Combining PARP inhibitors (PARPis) with immune checkpoint inhibitors may improve clinical outcomes in selected cancers. We evaluated rucaparib and atezolizumab in advanced gynaecological or triple-negative breast cancer (TNBC). METHODS: After identifying the recommended dose, patients with PARPi-naive BRCA-mutated or homologous recombination-deficient/loss-of-heterozygosity-high platinum-sensitive ovarian cancer or TNBC received rucaparib plus atezolizumab. Tumour biopsies were collected pre-treatment, during single-agent rucaparib run-in, and after starting combination therapy. RESULTS: The most common adverse events with rucaparib 600 mg twice daily and atezolizumab 1200 mg on Day 1 every 3 weeks were gastrointestinal effects, fatigue, liver enzyme elevations, and anaemia. Responding patients typically had BRCA-mutated tumours and higher pre-treatment tumour levels of PD-L1 and CD8 + T cells. Markers of DNA damage repair decreased during rucaparib run-in and combination treatment in responders, but typically increased in non-responders. Apoptosis signature expression showed the reverse. CD8 + T-cell activity and STING pathway activation increased during rucaparib run-in, increasing further with atezolizumab. CONCLUSIONS: In this small study, rucaparib plus atezolizumab demonstrated acceptable safety and activity in BRCA-mutated tumours. Increasing anti-tumour immunity and inflammation might be a key mechanism of action for clinical benefit from the combination, potentially guiding more targeted development of such regimens. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT03101280).
Publisher
Springer Nature
Keywords
Humans; Female; *Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage/adverse; effects/therapeutic use; *Triple Negative Breast Neoplasms/drug therapy/pathology; *Antibodies, Monoclonal, Humanized/administration & dosage/adverse; effects/therapeutic use; *Indoles/administration & dosage/adverse effects/therapeutic use; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects; Middle Aged; Aged; Adult; Ovarian Neoplasms/drug therapy/pathology/genetics; B7-H1 Antigen; BRCA1 Protein/genetics
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1038/s41416-024-02776-7
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-12 06:49:07
Last Modified: 2024-09-12 06:49:36

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙